{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VX-661&page=2", "query": { "intervention": "VX-661", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VX-661&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T13:01:00.070Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03447262", "title": "A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-659/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 484, "start_date": "2018-07-13", "completion_date": "2020-09-09", "has_results": true, "last_update_posted_date": "2022-01-25", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03447262" }, { "nct_id": "NCT03525548", "title": "A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-445/TEZ/IVA", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 113, "start_date": "2018-08-03", "completion_date": "2018-12-28", "has_results": true, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 28, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03525548" }, { "nct_id": "NCT03227471", "title": "A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "IVA", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "VX-445", "type": "DRUG" }, { "name": "Matched Placebo", "type": "DRUG" }, { "name": "TEZ", "type": "DRUG" }, { "name": "VX-561", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2017-01-23", "completion_date": "2018-03-27", "has_results": true, "last_update_posted_date": "2022-01-18", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 26, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Madera", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03227471" }, { "nct_id": "NCT05822102", "title": "Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [], "intervention_types": [], "sponsor": "National Jewish Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-02-09", "completion_date": "2023-09", "has_results": false, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 2, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05822102" }, { "nct_id": "NCT05033080", "title": "A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-121/TEZ/D-IVA", "type": "DRUG" }, { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo (matched to VX-121/TEZ/D-IVA)", "type": "DRUG" }, { "name": "Placebo (matched to ELX/TEZ/IVA)", "type": "DRUG" }, { "name": "Placebo (matched to IVA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 435, "start_date": "2021-09-14", "completion_date": "2023-11-21", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05033080" }, { "nct_id": "NCT05867147", "title": "An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Vanzacaftor", "type": "DRUG" }, { "name": "Vanzacaftor Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 56, "start_date": "2023-04-26", "completion_date": "2023-06-14", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867147" }, { "nct_id": "NCT03912233", "title": "A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-121", "type": "DRUG" }, { "name": "TEZ", "type": "DRUG" }, { "name": "VX-561", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2019-04-30", "completion_date": "2019-12-10", "has_results": true, "last_update_posted_date": "2023-04-20", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 12, "location_summary": "Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03912233" }, { "nct_id": "NCT03587961", "title": "Personalized Theratyping Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Symdeko", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Solomon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 20, "start_date": "2019-08-01", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587961" }, { "nct_id": "NCT04840862", "title": "Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Drug Drug Interaction" ], "interventions": [ { "name": "Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]", "type": "DRUG" }, { "name": "Rifabutin 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2022-05-09", "completion_date": "2024-05-30", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840862" }, { "nct_id": "NCT04056702", "title": "Impact of Triple Combination CFTR Therapy on Sinus Disease.", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Elexacaftor-tezacaftor-ivacaftor exposure", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennifer Taylor-Cousar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 31, "start_date": "2019-09-05", "completion_date": "2022-07", "has_results": false, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-09-24T13:01:00.070Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04056702" } ] }